The briefing
Researchers report that celastrol, derived from Tripterygium wilfordii, alleviated cholestatic liver injury and fibrosis in models by reshaping the liver’s immune environment. The findings point to a potential therapeutic avenue for cholestatic disease.
Original headline
Celastrol redirects immune cells to protect against cholestatic liver injury